Browsing by Author "Okay, Mufide"
Now showing items 1-4 of 4
-
Ankaferd Hemostat Affects Etoposide Resistance of the Malignant Melanoma Cells
Ghasemi, Mehdi; Okay, Mufide; Malkan, Umit Yavuz; Turk, Seyhan; Jabbar, Javaid; Hocaoglu, Helin; Haznedaroglu, Ibrahim Celalettin (Tıp Fakültesi, 2020-03-15)Kemoterapötik ilaçlara karşı direnç gelişimi, kanser tedavisinde bir engel haline gelmiştir. Ankaferd Hemostat’ın (ABS), melanom hücrelerinin proliferasyonunu baskıladığı gösterilmiştir; ancak mekanizması hakkında çok az ... -
The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia.
Ghasemi, Mehdi; Okay, Mufide; Turk, Seyhan; Naeemaee, Ronak; Guver, Ebru; Malkan, Umit Y; Aksu, Salih; Sayinalp, Nilgun; Haznedaroglu, Ibrahim Celalettin (Tıp Fakültesi, 2019-04-20)Introduction: Bone marrow renin-angiotensin system(RAS) modulates acute myeloid leukaemia(AML).The aim of this study is to clarify the relationships between RAS and AML, and to show the effect of losartan and doxorubicin ... -
Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide.
Turk, Seyhan; Turk, Can; Akbar, Muhammad Waqas; Kucukkaraduman, Baris; Isbilen, Murat; Demirkol Canli, Secil; Malkan, Umit Yavuz; Okay, Mufide; Ucar, Gulberk; Sayinalp, Nilgun; Haznedaroglu, Ibrahim Celalettin; Gure, Ali Osmay (Sağlık Hizmetleri Meslek Yüksekokulu, 2020-12-11)Despite the availability of various treatment protocols, response to therapy in patients with Acute Myeloid Leukemia (AML) remains largely unpredictable. Transcriptomic profiling studies have thus far revealed the presence ... -
The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
Turk, Can; Okay, Mufide; Turk, Seyhan; Temirci, Elif Sena; Javad, Osama; Aksu, Sal; Sayinalp, Nilgun; Haznedaroglu, Ibrahim Celalettin (2019)
DSpace@LokmanHekim by Lokman Hekim University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..
